


**IN THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application.


147. (Previously presented) Crystalline atorvastatin hemi-calcium and solvates thereof characterized by a physical or spectroscopic analysis result selected from the group consisting of:
- a) a powder X-ray diffraction pattern generated using CuK<sub>α</sub> radiation with peaks at 4.8, 5.2, 8.0, 9.2, 9.6, 19.0, 20.0, 24.0 and 29.0±0.2 degrees two-theta;
  - b) a powder X-ray diffraction pattern generated using CuK<sub>α</sub> radiation with peaks at 9.3, 9.6, 19.2, 20.0, 21.6, 22.4 and 23.9±0.2 degrees two-theta;
  - c) *d*-spacings of about 30.81, 18.46, 16.96, 15.39, 14.90, 12.78, 11.05, 9.58, 9.22, 7.42, 6.15, 5.43, 4.62, 4.44, and 3.98Å;
  - d) a monoclinic unit cell with cell parameters:  $a=18.55\text{--}18.7 \text{ \AA}$ ,  $b=5.52\text{--}5.53 \text{ \AA}$ ,  $c=31.0\text{--}31.2 \text{ \AA}$  and  $\beta=97.5\text{--}99.5$
  - e) a solid state cross-polarization/magic angle spinning <sup>13</sup>C nuclear magnetic resonance spectrum with resonances at 24.8, 25.2, 26.1, 119.5, 120.1, 121.8, 122.8, 126.6, 128.8, 129.2, 134.2, 135.1, 137.0, 138.3 and 139.8±0.1 parts per million; and
  - f) a solid state cross-polarization/magic angle spinning <sup>13</sup>C nuclear magnetic resonance spectrum wherein the chemical shift differences between the lowest resonance and other resonances are: 2.2, 7.0, 7.4, 8.3, 22.5, 23.0, 23.7, 25.6, 26.3, 28.3, 53.0, 55.5, 96.3, 98.2, 101.7, 102.3, 104.0, 105.0, 108.8, 111.0,

111.4, 116.4, 117.3, 119.2, 120.5, 122.0, 142.0, 148.6, 161.0 and 168.7 parts per million.

148. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 wherein the result is the powder X-ray diffraction pattern with peaks at 4.8, 5.2, 8.0, 9.2, 9.6, 19.0, 20.0, 24.0 and  $29.0 \pm 0.2$  degrees two-theta.
149. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 148 wherein the powder X-ray diffraction pattern has peaks at 11.9, 17.3, 21.5 and  $22.3 \pm 0.2$  degrees two-theta.
150. (Currently amended) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 149 characterized by a powder X-ray diffraction pattern generated using  $\text{CuK}_\alpha$  radiation substantially as depicted in FIG 3 follows




151. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 wherein the result is the powder X-ray diffraction pattern with peaks at 9.3, 9.6, 19.2, 20.0, 21.6, 22.4 and  $23.9 \pm 0.2$  degrees two-theta.
152. (Currently amended) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 148 characterized by a powder X-ray diffraction pattern generated using  $\text{CuK}_\alpha$  radiation substantially as depicted in FIG 3 follows



153. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 151 wherein the powder X-ray diffraction pattern further has a peak at 16.3 degrees two-theta.

154. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 151 wherein the powder X-ray diffraction pattern further includes peaks at 17.1 (broad), 24.7, 25.6, 26.5±0.2 degrees two-theta.
155. (Currently amended) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 wherein the result is the *d*-spacings and the crystalline atorvastatin hemi-calcium and solvates thereof is further characterized by a high resolution powder X-ray diffraction pattern substantially as shown in FIG 4 follows




when irradiated with X-rays with a wavelength of about 1.15Å.

156. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 wherein the result is a solid state cross-polarization/magic angle spinning  $^{13}\text{C}$  nuclear magnetic resonance spectrum with resonances at 24.8, 25.2, 26.1, 119.5, 120.1, 121.8, 122.8, 126.6, 128.8, 129.2, 134.2, 135.1, 137.0, 138.3 and 139.8±0.1 parts per million and the spectrum further includes resonances at 17.8, 20.0, 40.3,

40.8, 41.5, 43.4, 44.1, 46.1, 70.8, 73.3, 114.1, 116.0, 159.8, 166.4, 178.8 and  
186.5±0.1 parts per million.

157. (Currently amended) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 wherein the result is a solid state cross-polarization/magic angle spinning  $^{13}\text{C}$  nuclear magnetic resonance spectrum with resonances at 24.8, 25.2, 26.1, 119.5, 120.1, 121.8, 122.8, 126.6, 128.8, 129.2, 134.2, 135.1, 137.0, 138.3 and 139.8±0.1 parts per million and the spectrum is substantially as depicted in FIG-5 follows



158. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 having a water content of up to 7%.

159. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 that is a trihydrate.
160. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 containing up to about four moles of water.
161. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 containing up to about 3% ethanol.
162. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 having a narrow particle size distribution.
163. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 162 wherein all of the particles are 100 microns or less in diameter.
164. (Previously presented) The crystalline atorvastatin hemi-calcium and solvates thereof of claim 163 wherein all of the particles are 50 microns or less in diameter.
165. (Previously presented) Crystalline atorvastatin hemi-calcium Form VIII ethanolate.
166. (Previously presented) The crystalline atorvastatin hemi-calcium ethanolate of claim 165 containing up to about 3 % ethanol.

167-184. (Canceled)

185. (Previously presented) A pharmaceutical composition comprising the crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 and at least one pharmaceutical excipient.

186. (Previously presented) A pharmaceutical dosage form comprising the crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 and at least one pharmaceutical excipient.

187. (Previously presented) Use of the crystalline atorvastatin hemi-calcium and solvates thereof of claim 147 to prepare a pharmaceutical composition or dosage form.

188. (Previously presented) A method of reducing low density lipoprotein particle concentration in the blood stream of a patient by administering the crystalline atorvastatin hemi-calcium or solvate thereof of claim 147.